<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02528422</url>
  </required_header>
  <id_info>
    <org_study_id>MY-1-2014</org_study_id>
    <secondary_id>2014-004496-23</secondary_id>
    <nct_id>NCT02528422</nct_id>
  </id_info>
  <brief_title>The Effect of Acyl-Ghrelin on Kidney Function and Blood Pressure in Healthy Volunteers</brief_title>
  <acronym>DOAG</acronym>
  <official_title>The Effect of Acyl-Ghrelin on Kidney Function and Blood Pressure in Healthy Volunteers - A Randomized, Cross-over, Single-blind, Placebo-controlled Dose-response Study of the Acyl-ghrelin Induced Effects on GFR, Tubular Transport of Sodium and Water in Different Nephron Segments and Central and Peripheral Blood Pressure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Erling Bjerregaard Pedersen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Aarhus</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Regional Hospital Holstebro</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Ghrelin (growth hormone release inducer) is produced in the stomach. The active form of
      Ghrelin is Acyl-Ghrelin. Acyl-Ghrelin stimulates the Ghrelin receptors. Ghrelin receptors are
      detected in the distal tubules in mice and animal studies have shown that Ghrelin increases
      the absorption of sodium in the renal tubules. Ghrelin infusion directly into the renal
      artery of rats increased sodium reabsorption in the distal nephron, presumably via the
      epithelial sodium channels (ENaC).

      The purpose of the study is to measure the acyl-ghrelin induced effects on GFR, tubular
      transport of sodium and water in different nephron segments and central and peripheral blood
      pressure in a randomized, cross-over, single-blind, placebo-controlled dose-response study.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>May 2015</start_date>
  <completion_date type="Anticipated">January 2018</completion_date>
  <primary_completion_date type="Anticipated">January 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Fractional sodium excreation (FENa)</measure>
    <time_frame>5-6 Hours</time_frame>
    <description>Measurement of FENa at baseline and after Acyl-Ghrelin injection</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Renal function</measure>
    <time_frame>5-6 Hours</time_frame>
    <description>Measurement of GFR, FEK and CH20 at baseline and after Acyl-Ghrelin injection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Water and sodium transport</measure>
    <time_frame>5-6 Hours</time_frame>
    <description>Measurement of u-AQP2, u-NCC , u-NKCC -2 and u-ENaC at baseline and after Acyl-Ghrelin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vasoactive hormones</measure>
    <time_frame>5-6 Hours</time_frame>
    <description>Measurement of p-BNP , PRC, p-AngII , p-Aldo and p-AVP at baseline and after Acyl-Ghrelin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood pressure</measure>
    <time_frame>5-6 Hours</time_frame>
    <description>Measurement of Central blood pressure, PWV, AIx and Peripheral blood pressure at baseline and after Acyl-Ghrelin</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Renal Tubular Transport</condition>
  <arm_group>
    <arm_group_label>50 µg Acyl-Ghrelin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intravenous injection on examination day.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>100 µg Acyl-Ghrelin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intravenous injection on examination day.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Isotonic Sodium Chloride</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Intravenous injection on examination day.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Acyl-Ghrelin</intervention_name>
    <arm_group_label>50 µg Acyl-Ghrelin</arm_group_label>
    <arm_group_label>100 µg Acyl-Ghrelin</arm_group_label>
    <arm_group_label>Isotonic Sodium Chloride</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18-40 years,

          -  BMI 18,5-30kg/m2,

          -  women must use contraception.

        Exclusion Criteria:

          -  Tobacco smoking,

          -  substance abuse,

          -  consumption of more than 7 units of alcohol/week for women and more than 14 units/week
             for men,

          -  medical treatment except for contraception,

          -  pregnancy or nursing,

          -  allergy to acyl-ghrelin,

          -  significant clinical signs of heart-, lung-, liver-, kidney-, endocrine-, brain- or
             neoplastic disorders,

          -  clinically significant abnormal findings in screening blood samples,

          -  urine sample or ECG,

          -  office blood pressure over 140/90 mmHg,

          -  donation of blood within 1 month of the first day of investigation.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Erling B Pedersen</last_name>
    <role>Study Chair</role>
    <affiliation>Department of Medical Research and Medicine, Holstebro Regional Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>My ES Malmberg</last_name>
    <phone>+4578436588</phone>
    <email>mymalmbe@rm.dk</email>
  </overall_contact>
  <location>
    <facility>
      <name>Department of Medical Research, Regional Hospital Holstebro</name>
      <address>
        <city>Holstebro</city>
        <zip>7500</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>August 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 17, 2015</study_first_submitted>
  <study_first_submitted_qc>August 18, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 19, 2015</study_first_posted>
  <last_update_submitted>August 18, 2015</last_update_submitted>
  <last_update_submitted_qc>August 18, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 19, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Regional Hospital Holstebro</investigator_affiliation>
    <investigator_full_name>Erling Bjerregaard Pedersen</investigator_full_name>
    <investigator_title>Professor, MD, Dr.Sci.</investigator_title>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

